Objective To compare two oral contraceptive pills, both containing 150 μg desogestrel, but
with either 20 μg (Mercilon®) or 30 μg (Marvelon®/Desolett®) ethinyl oestradiol (EE) …

Efficacy, cycle control, tolerance, and adverse events were studied in a clinical Phase IV
study using a new progestogen, gestodene, in an amount of 75 μg combined with 30 μg …

The clinical and metabolic effects of a short-term treatment with a combination contraceptive
pill containing 30 mcg ethinylestradiol and 75 mcg gestodene were evaluated in a group of …

OBJECTIVE: A prospective, open-label, noncomparative, multicenter study was carried out
in 163 women aged 18–39 (mean 25±5 years), who used an ultra-low-dose oral …

This prospective, double-blind, randomized study was conducted to compare the
contraceptive reliability, cycle control, and tolerability of a 23-day versus a 21-day oral …

The new low-dose combination oral contraceptive (OC) containing 75 micrograms of the
new progestogen gestodene (GTD) plus 30 micrograms ethinyl estradiol (EE) was clinically …

Objectives: The safety and contraceptive efficacy of a new 24-day regimen of an oral
contraceptive combination containing gestodene (GTD) 60 µg and ethinylestradiol (EE) 15 …

This clinical investigation of a low-dose, monophasic gestodene-containing oral
contraceptive (75 μg gestodene/30 μg ethinylestradiol), investigated contraceptive efficacy …

In three ongoing open studies conducted by 50 investigators in Europe, South America, and
New Zealand, 639 subjects followed a new triphasic regimen of gestodene (GTD) and …

This was an open-label multicenter study to compare the cycle control and effect on well-
being of two oral contraceptives containing gestodene and one containing desogestrel. A …